Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Pleural Mesothelioma

Pleural Mesothelioma

Part of Cancer

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Pleural Mesothelioma

12 trials tracked for Pleural Mesothelioma: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 75 citations.

12Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 8 Phase 1 1 Other / NA 1
  1. Phase 3 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Completed · 75 cited
  2. Phase 3 Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma Completed
  3. Phase 2 A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma Completed
  4. Phase 2 Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma Completed
  5. Phase 2 Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy Completed
  6. Phase 2 An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma Completed
Show 6 more trials
  1. Phase 2 Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma Completed
  2. Phase 2 Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) Completed
  3. Phase 2 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Completed
  4. Phase 2 Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity Completed
  5. Phase 1 Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma Completed
  6. N/A Alvopem® (Pemetrexed) Safety Assessment Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Pleural Mesothelioma: what the trials found

Clinical evidence for pleural mesothelioma includes the evaluation of NGR-hTNF in combination with Best Investigator's Choice (BIC). In a Phase 3 trial, the Disease Control Rate (DCR) was reported as 114, 109, 3, 6, 111, and 103 (p=0.62), while the number of participants achieving disease control for at least 6 months was 84 and 76 1.

The use of rAd-IFN in a Phase 3 trial showed a Disease Control Rate (DCR) of 19 and 15 (p=1.0000), with a Clinical Benefit Rate (CBR) of 9 and 9 (p=0.7665) 2.

Recent results — preliminary, needs further review

  • Galinpepimut-S + Montanide + GM-CSF (Phase 2, N=41) 3
  • Cisplatin (Phase 2, N=34) 4
  • MORAb-009 (Amatuximab) (Phase 2, N=89) 5
  • BBI608 (Phase 2, N=28) 6
  • pemetrexed, cisplatin and CBP501 (Phase 2, N=69) 7

For the clinician treating this condition

  • NGR-hTNF combined with Best Investigator's Choice demonstrated a reported Disease Control Rate in Phase 3 trials 1.
  • rAd-IFN showed consistent Clinical Benefit Rates and Disease Control Rates in Phase 3 investigations 2.

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
HITHOC with cytoreductive surgery improves survival in pleural mesothelioma without raising early postoperative risk
Pulmonology & Critical Care Meta-analysis
HITHOC with cytoreductive surgery improves survival in pleural mesothelioma without raising early postoperative risk Heat treatment shows survival benefit for pleural mesothelioma patients
A meta-analysis of 6 studies (n=1060) found that adding hyperthermic intrathoracic chemotherapy (HITHOC) to cytoreductive surgery for pleura…
A new analysis shows that adding heat to chemotherapy during surgery can extend life for people with a rare type of lung cancer.
Jul 4, 2026
Tumor Treating Fields may disrupt tumor communication and induce conditional BRCAness in malignant pleural mesothelioma
Allergy & Immunology Sys. Review
Tumor Treating Fields may disrupt tumor communication and induce conditional BRCAness in malignant pleural mesothelioma New review explains how Tumor Treating Fields disrupts cancer cell networks in mesothelioma
This review explores the theoretical mechanisms of Tumor Treating Fields (TTFields) in malignant pleural mesothelioma. The authors describe …
A new review explains how Tumor Treating Fields disrupts cancer cell networks and changes the immune environment in malignant pleural mesoth…
Frontiers Jun 1, 2026
Pemetrexed use associated with disproportionate reporting of blood, endocrine, and renal disorders in FAERS data
Rheumatology Cohort
Pemetrexed use associated with disproportionate reporting of blood, endocrine, and renal disorders in FAERS data Your Lung Cancer Drug May Have Side Effects Not on the Label
This pharmacovigilance study analyzed 27,098 pemetrexed-associated reports in the US FAERS database from 2004 to 2024.
A safety review of over 27,000 reports found that the lung cancer drug pemetrexed may cause side effects not currently listed on its officia…
Frontiers Apr 16, 2026
Nivolumab+ipilimumab shows 5-year OS benefit (14% vs 6%) vs chemo in unresectable pleural mesothelioma
Oncology RCT
Nivolumab+ipilimumab shows 5-year OS benefit (14% vs 6%) vs chemo in unresectable pleural mesothelioma Can immunotherapy help people with advanced mesothelioma live longer? Five-year results show it can
In the 5-year follow-up of CheckMate 743, nivolumab plus ipilimumab demonstrated continued overall survival benefit versus chemotherapy in u…
Five years after starting treatment, 14% of advanced mesothelioma patients survived on immunotherapy versus 6% on chemotherapy, proving last…
Mar 30, 2026
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma
Pulmonology & Critical Care Phase II
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma Could This New Drug Offer Hope for Patients with Returning Pleural Mesothelioma?
A Phase II trial evaluates ivonescimab in 38 pleural mesothelioma patients post-immunotherapy/chemotherapy. The study aims for a ≥55% diseas…
Patients with returning pleural mesothelioma may find hope in ivonescimab, a new drug being tested to control stubborn cancer after standard…
CT.gov Mar 27, 2026

Research across Cancer

Related studies from across the Cancer family.

Review of a case report on epithelioid clear cell mesothelioma in a 76-year-old male with 24 months follow-up
Oncology Sys. Review
Review of a case report on epithelioid clear cell mesothelioma in a 76-year-old male with 24 months follow-up A 76-year-old man with rare cancer stayed cancer-free for two years
This publication is a review of a single case report involving a 76-year-old male with epithelioid clear cell mesothelioma. The patient had …
A 76-year-old man with a rare form of cancer had no signs of the disease returning after two years, offering hope for others facing this dif…
Frontiers May 18, 2026

Questions about Pleural Mesothelioma

Does nivolumab and ipilimumab provide a 5-year survival benefit for pleural mesothelioma?

Yes, nivolumab plus ipilimumab provides a 5-year survival benefit for pleural mesothelioma, with 14% vs 6% survival rates compared to chemotherapy.

Full answer →
Does HITHOC with surgery improve survival for pleural mesothelioma patients?

Yes, adding HITHOC to surgery modestly improves survival for pleural mesothelioma patients without raising early postoperative risk, based on recent meta-analyses.

Full answer →